Lupin said that its wholly owned subsidiary VISUfarma B.V. has entered into an exclusive licensing agreement with USA-based Visus Therapeutics Inc. for commercializing ‘YUVEZZI’ in the European Union, United Kingdom, Switzerland, Norway, and Iceland.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.